TP53 and prostate cancer: Both p53-dependent and p53-independent antiproliferative effects of urolithin A were demonstrated in the three human prostate cancer lines with different p53 activities, namely, LNCaP (p53+/+), 22RV1 (p53−/+), and PC3 (p53−/−) cells.